Cargando…
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
Background: This study investigated the impact of baseline liver function according to the Child–Pugh score and ALBI (albumin-bilirubin) grade on the outcomes of patients with unresectable hepatocellular carcinoma treated with lenvatinib. Methods: A total of 82 lenvatinib treated patients were inclu...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678474/ https://www.ncbi.nlm.nih.gov/pubmed/31284682 http://dx.doi.org/10.3390/cancers11070952 |
_version_ | 1783441109622456320 |
---|---|
author | Ueshima, Kazuomi Nishida, Naoshi Hagiwara, Satoru Aoki, Tomoko Minami, Tomohiro Chishina, Hirokazu Takita, Masahiro Minami, Yasunori Ida, Hiroshi Takenaka, Mamoru Sakurai, Toshiharu Watanabe, Tomohiro Morita, Masahiro Ogawa, Chikara Hiraoka, Atsushi Johnson, Philip Kudo, Masatoshi |
author_facet | Ueshima, Kazuomi Nishida, Naoshi Hagiwara, Satoru Aoki, Tomoko Minami, Tomohiro Chishina, Hirokazu Takita, Masahiro Minami, Yasunori Ida, Hiroshi Takenaka, Mamoru Sakurai, Toshiharu Watanabe, Tomohiro Morita, Masahiro Ogawa, Chikara Hiraoka, Atsushi Johnson, Philip Kudo, Masatoshi |
author_sort | Ueshima, Kazuomi |
collection | PubMed |
description | Background: This study investigated the impact of baseline liver function according to the Child–Pugh score and ALBI (albumin-bilirubin) grade on the outcomes of patients with unresectable hepatocellular carcinoma treated with lenvatinib. Methods: A total of 82 lenvatinib treated patients were included. The correlations of baseline liver function according to the Child–Pugh score and ALBI grade with treatment outcomes, including objective response rate per mRECIST (modified Response Evaluation Criteria in the Solid Tumor), time to treatment failure, treatment duration, and likelihood of treatment discontinuation due to adverse events, were assessed in patients with hepatocellular carcinoma treated with lenvatinib. Patients were divided into four groups: (1) Child–Pugh score 5 and ALBI grade 1 (group 1), (2) Child–Pugh score 5 and ALBI grade 2 (group 2), (3) Child–Pugh score 6 (group 3), and (4) Child–Pugh score ≥7 (group 4). Univariate and multivariate analyses were performed to identify the factors contributing to the objective response rate and likelihood of discontinuation due to adverse events. Results: Among the 82 patients analyzed, group 1 had the highest objective response rate (57.1%) and the lowest likelihood of treatment discontinuation because of adverse events (11.1%) among the four groups (p < 0.05 and p < 0.05). Multivariate analysis identified ALBI grade 1 and baseline AFP level <200 ng/mL as the significant predictors of a high objective response rate (p < 0.05 and p < 0.01), and confirmed that patients with ALBI grade 1 had the lowest probability of treatment discontinuation due to adverse events (p < 0.01). Conclusions: Patients with Child–Pugh score of 5 and ALBI grade 1 predicted a higher response rate and lower treatment discontinuation due to adverse events by lenvatinib treatment. |
format | Online Article Text |
id | pubmed-6678474 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66784742019-08-19 Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study Ueshima, Kazuomi Nishida, Naoshi Hagiwara, Satoru Aoki, Tomoko Minami, Tomohiro Chishina, Hirokazu Takita, Masahiro Minami, Yasunori Ida, Hiroshi Takenaka, Mamoru Sakurai, Toshiharu Watanabe, Tomohiro Morita, Masahiro Ogawa, Chikara Hiraoka, Atsushi Johnson, Philip Kudo, Masatoshi Cancers (Basel) Article Background: This study investigated the impact of baseline liver function according to the Child–Pugh score and ALBI (albumin-bilirubin) grade on the outcomes of patients with unresectable hepatocellular carcinoma treated with lenvatinib. Methods: A total of 82 lenvatinib treated patients were included. The correlations of baseline liver function according to the Child–Pugh score and ALBI grade with treatment outcomes, including objective response rate per mRECIST (modified Response Evaluation Criteria in the Solid Tumor), time to treatment failure, treatment duration, and likelihood of treatment discontinuation due to adverse events, were assessed in patients with hepatocellular carcinoma treated with lenvatinib. Patients were divided into four groups: (1) Child–Pugh score 5 and ALBI grade 1 (group 1), (2) Child–Pugh score 5 and ALBI grade 2 (group 2), (3) Child–Pugh score 6 (group 3), and (4) Child–Pugh score ≥7 (group 4). Univariate and multivariate analyses were performed to identify the factors contributing to the objective response rate and likelihood of discontinuation due to adverse events. Results: Among the 82 patients analyzed, group 1 had the highest objective response rate (57.1%) and the lowest likelihood of treatment discontinuation because of adverse events (11.1%) among the four groups (p < 0.05 and p < 0.05). Multivariate analysis identified ALBI grade 1 and baseline AFP level <200 ng/mL as the significant predictors of a high objective response rate (p < 0.05 and p < 0.01), and confirmed that patients with ALBI grade 1 had the lowest probability of treatment discontinuation due to adverse events (p < 0.01). Conclusions: Patients with Child–Pugh score of 5 and ALBI grade 1 predicted a higher response rate and lower treatment discontinuation due to adverse events by lenvatinib treatment. MDPI 2019-07-07 /pmc/articles/PMC6678474/ /pubmed/31284682 http://dx.doi.org/10.3390/cancers11070952 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ueshima, Kazuomi Nishida, Naoshi Hagiwara, Satoru Aoki, Tomoko Minami, Tomohiro Chishina, Hirokazu Takita, Masahiro Minami, Yasunori Ida, Hiroshi Takenaka, Mamoru Sakurai, Toshiharu Watanabe, Tomohiro Morita, Masahiro Ogawa, Chikara Hiraoka, Atsushi Johnson, Philip Kudo, Masatoshi Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study |
title | Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study |
title_full | Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study |
title_fullStr | Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study |
title_full_unstemmed | Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study |
title_short | Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study |
title_sort | impact of baseline albi grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678474/ https://www.ncbi.nlm.nih.gov/pubmed/31284682 http://dx.doi.org/10.3390/cancers11070952 |
work_keys_str_mv | AT ueshimakazuomi impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT nishidanaoshi impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT hagiwarasatoru impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT aokitomoko impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT minamitomohiro impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT chishinahirokazu impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT takitamasahiro impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT minamiyasunori impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT idahiroshi impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT takenakamamoru impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT sakuraitoshiharu impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT watanabetomohiro impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT moritamasahiro impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT ogawachikara impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT hiraokaatsushi impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT johnsonphilip impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy AT kudomasatoshi impactofbaselinealbigradeontheoutcomesofhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenterstudy |